Researchers from Trinity College Dublin have taken a leap forward in understanding how we might fight back against the potentially deadly MRSA bacterium. They have shown in an animal model that targeting a key suppressive immune molecule (IL-10) during the delivery of a vaccine improves the ability of the vaccine to protect against infection. The bacterium Staphylococcus aureus is one of the leading causes of community- and hospital-acquired bacterial infection, and is associated with over one million deaths worldwide each year.
Unfortunately, antibiotics are becoming increasingly less effective against this bacterium with the antibiotic-resistant form, MRSA, responsible for the highest number of deaths in high-income countries that are attributable to antimicrobial resistant bacterial infections. As a result, scientists are keenly focused on finding solutions to turn the tide in fighting S. aureus- related infections.
One hugely appealing option is a vaccine but, while some progress has been made on that front in recent years, a number of major hurdles remain. One of these appears to be the bacterium's ability to dampen the immune response by turning on one of the natural breaks that exists within the immune system, an important immune-suppressive molecule known as Interleukin-10 (IL-10), which acts to reduce inflammation in the body. The interesting thing about S.
aureus is that in addition to being a deadly pathogen, forms of this bacteria live in and on our bodies without.
